Recent developments include Lantheus reporting third quarter 2026 revenue of $389.9 million, receiving an FTC second request regarding its pending merger, and obtaining FDA approvals for key imaging agents including Bravnetsa and TAUKLARIFY.

• Lantheus Holdings, Inc. reported third quarter 2026 revenue of $389.9 million [N1].
• The company received a second request from the Federal Trade Commission related to its pending merger with Curium US Holdings LLC, extending the regulatory review period [N2].
• FDA approved Lantheus' Bravnetsa as equivalent to Lutathera for neuroendocrine tumors [N4].
• Lantheus obtained FDA approval for TAUKLARIFY, a tau PET imaging agent for Alzheimer's disease [N5].
• The company announced FDA approval of PYLARIFY TruVu, a new formulation of its PSMA PET imaging agent, with CMS granting a HCPCS code and temporary pass-through status effective October 1, 2026 [N5].

Lantheus has secured FDA approvals for multiple imaging agents, expanding its product portfolio in oncology and neurodegenerative disease diagnostics. The recent approval of PYLARIFY TruVu with enhanced stability and manufacturing efficiency could improve supply chain scalability. The pending merger with Curium US Holdings LLC, if completed, may provide strategic benefits and financial resources. The company's strong liquidity position supports ongoing operations and potential investments. Successful resolution of manufacturing issues for LNTH-2501 and market acceptance of new products could enhance revenue streams. Collaborations and licensing deals, such as with GE HealthCare, may facilitate geographic expansion and product adoption.

The pending merger faces regulatory hurdles including an FTC second request, which may delay or prevent completion. Failure to complete the merger could result in significant termination fees, litigation costs, and operational disruptions. Manufacturing issues have delayed FDA approval of LNTH-2501, with no assurance of timely resolution. Market acceptance, coding, coverage, and reimbursement for new products remain uncertain, posing commercialization risks. Operational restrictions under the merger agreement may limit business flexibility. Litigation related to the merger could impose financial and reputational costs. Competitive pressures and regulatory complexities in the diagnostic imaging market may impact growth prospects.

Lantheus Holdings' moat is supported by its portfolio of FDA-approved diagnostic imaging agents, including proprietary PET imaging products for oncology and Alzheimer's disease. The company's regulatory approvals and coding designations, such as HCPCS and CMS pass-through status, provide market access advantages. Strategic collaborations and licensing agreements, including with GE HealthCare, enhance its distribution and development capabilities. The complexity of manufacturing and regulatory compliance for imaging agents creates barriers to entry for competitors. However, the company faces risks from regulatory delays, manufacturing challenges, and competitive pressures in the diagnostic imaging market.

• Merger Completion Risk: The pending merger with Curium US Holdings LLC is subject to regulatory approvals including an FTC second request, which extends the waiting period and may delay or prevent completion. Failure to complete the merger could result in termination fees of $228 million, litigation, negative publicity, and operational disruptions.
• Regulatory and Manufacturing Risks: FDA approval of LNTH-2501 has been delayed due to unresolved third-party manufacturing facility conditions. There is uncertainty regarding the timing and success of resolving these issues and obtaining approval. Manufacturing scale-up and supply chain complexities pose additional risks for new product launches.
• Operational Restrictions: Under the merger agreement, Lantheus faces restrictions on capital expenditures, indebtedness, clinical studies, and other business activities, potentially limiting operational flexibility and delaying strategic initiatives.
• Litigation Risks: Stockholder lawsuits have been filed alleging omissions or misrepresentations in merger-related disclosures. Additional litigation may arise, imposing financial costs and reputational risks.
• Market Acceptance and Reimbursement: New products such as PYLARIFY TruVu and LNTH-2501 face uncertainties in market adoption, coding, coverage, and payment. Temporary CMS pass-through status for PYLARIFY TruVu may not continue, affecting reimbursement.

• Lantheus Holdings, Inc. operates in the healthcare sector with a focus on diagnostic imaging agents and related products.
• The company reported third quarter 2026 revenue of $389.9 million as of November 6, 2026.
• As of September 30, 2026, Lantheus had cash and cash equivalents of $683.61 million and current assets of $1.12371 billion, with current liabilities of $345.967 million, resulting in a current ratio of 3.25 and a cash ratio of 1.98, indicating strong liquidity.
• Net income for the quarter ended September 30, 2026, was $22.371 million with basic and diluted EPS of $0.34 and $0.33 respectively.
• Lantheus is in the process of a pending merger with Curium US Holdings LLC, subject to customary closing conditions and regulatory approvals, including an FTC second request received on October 21, 2026, which extends the Hart-Scott-Rodino waiting period.
• The merger consideration includes $102.50 per share in cash plus a contingent value right (CVR) up to $12.00 per share, contingent on milestone achievements.
• The company faces risks related to the merger including potential delays, termination fees of $228 million under certain conditions, litigation from stockholders, and operational restrictions under the merger agreement.
• Lantheus has received FDA approvals for several products including PYLARIFY TruVu (a new formulation of its PSMA PET imaging agent), Bravnetsa (equivalent to Lutathera for neuroendocrine tumors), and TAUKLARIFY (a tau PET imaging agent for Alzheimer's disease).
• PYLARIFY TruVu received a Healthcare Common Procedure Coding System (HCPCS) code effective October 1, 2026, and Temporary Pass-Through (TPT) status granted by CMS, though TPT status is temporary and future coding, coverage, and payment remain uncertain.
• The company acquired rights to LNTH-2501, a diagnostic kit with an FDA NDA under review; the FDA issued a Complete Response Letter in June 2026 citing unresolved third-party manufacturing facility conditions, delaying approval.
• Lantheus has operational and strategic risks related to product launches, manufacturing scale-up, market acceptance, and payer reimbursement for new products.
• The company has incurred and expects to incur significant costs related to the merger process, including regulatory and professional fees, which may not yield benefits if the merger is not completed.
• Lantheus' management attention is partially diverted to merger completion efforts, which may affect day-to-day operations and strategic initiatives.
• The company faces risks of adverse impacts on relationships with employees, collaborators, customers, regulators, and suppliers due to merger uncertainty.
• Lawsuits related to the merger have been filed by stockholders alleging omissions or misrepresentations in proxy statements; additional litigation may occur.
• The merger agreement restricts Lantheus' ability to undertake certain business actions without approval from the merger parent, potentially limiting operational flexibility.
• Lantheus has licensing agreements and collaborations, including with GE HealthCare for PYLARIFY in Japan.
• The company has a portfolio of clinical development candidates targeting diagnostic imaging in oncology and Alzheimer's disease, including NAV-4694 in Phase 3 development.
• Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.